RxDoctor Payments Data

Hector Martinez Gonzalez, MD

Interventional Cardiology · Mayaguez, PRNPI 1902008352

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $189,060 of the $260,590 with a category attached, or 72.6%. 22 manufacturers reported payments, led by Johnson & Johnson at 52.9% of the total. Reporting peaked in 2021 at $65,211 and has fallen 71.0% since, to $18,917 in 2025. Among interventional cardiology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$260,590in general payments, 2019–2025

Across 618 payments — averaging $421.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$138K
  • Abbott$55K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27K
  • Boston Scientific$22K
  • Medtronic$12K
  • Terumo Medical Corporation$4K
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$45,93018%
  • Speaking & faculty fees$189,06073%
  • Travel & lodging$8,7223%
  • Food & beverage$16,8036%
  • Gifts$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson109$137,750
Abbott122$54,550
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)69$27,075
Boston Scientific135$21,888
Medtronic(2 entities)109$12,211
Terumo Medical Corporation3$4,040
Boehringer Ingelheim8$611
AstraZeneca13$449
E.r. Squibb & Sons, L.L.C.9$435
Edwards Lifesciences2$282
Amgen6$245
Merck3$192
Bayer2$191
PBG Puerto Rico LLC10$178
Bayer Puerto Rico Inc.5$114
Novartis5$110
Chiesi USA, Inc.3$108
Pfizer Pharmaceuticals LLC1$64
Asahi Intecc USA, Inc.1$51
Cordis US CORP.1$20
AbbVie1$17
Cardinal Health P.r. 120 Inc1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$260,590 in reported general payments places this provider in the 90th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$31,429
Medicare patients
136
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol164$134,083
XareltoRivaroxaban113$79,764
BrilintaTicagrelor69$35,058
Candesartan Cilexetil107$13,730
EliquisApixaban19$10,185
ClopidogrelClopidogrel Bisulfate528$7,055
Ranolazine ErRanolazine64$6,729
Rosuvastatin Calcium486$6,377
Metoprolol Succinate298$5,231
Doxazosin Mesylate163$4,637
Ezetimibe163$3,662
Isosorbide Mononitrate ErIsosorbide Mononitrate126$2,521
Losartan Potassium166$2,431
Bumetanide46$1,882
Irbesartan39$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$449$169,141233 claims
Johnson & JohnsonXarelto$137,750$79,764113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →